

For Internal Use Only
Sec File No. 9-

91-1439

Submit 1 Original
and 9 copies

OMB APPROVAL
OMB Number: 3235-0504
Expires July 31, 2004
Estimated average burden
hours per response

SECURITIES AND EXCHANGE COMMISSION
RECEIVED

~~611430~~

OCT 31 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDED FORM 19b-4(e)



DIVISION OF MARKET REGULATION

Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I Initial Listing Report

- 1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:
International Securities Exchange, LLC
- 2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
iShares Trust
- 3. Class of New Derivative Securities Product:
Investment Company Unit
- 4. Name of Underlying Instrument:
iShares Nasdaq Biotechnology Index, iShares Dow Jones U.S. Real Estate Index
- 5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-based:
The indexes referred to in Item 4 above are narrow-based indexes
- 6. Ticker Symbol(s) of New Derivative Securities Product:
IBB, IYR
- 7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:
New York Stock Exchange, Nasdaq Global Market and American Stock Exchange
- 8. Settlement Methodology of New Derivative Securities Product:
T+3, Physical Settlement
- 9. Position Limits of New Derivative Securities Product (if applicable):
Not Applicable

PROCESSED

MAR 20 2007

E THOMSON
FINANCIAL

Part II Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: **Michael J. Simon**

Title: **General Counsel and Secretary**

Telephone Number: **212-897-9230**

Manual Signature of Official Responsible for Form: *[Signature]*

Date: **October 31, 2006**

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	OCTOBER 31, 2006

SECURITIES AND EXCHANGE COMMISSION

OCT 31 2006

DIVISION OF MARKET REGULATION



INTERNATIONAL SECURITIES EXCHANGE.

60 Broad Street New York, NY 10004
TEL: 212 943-2400
FAX: 212 425-4926
www.iseoptions.com

October 31, 2006

By Facsimile and Overnight Courier

Gail S. Jackson
Paralegal Specialist
US Securities and Exchange Commission
Division of Market Regulation
100 F Street, NE – Room 6628
Washington, DC 20549

Re: Amended Forms 19b-4(e)s related to: Dow Industry Diamonds; iShares Russell 2000 Index Fund; iShares Russell 2000 Value Index Fund; iShares Russell 2000 Growth Index Fund; iShares S&P 500 Index Fund; iShares S&P Small Cap 600 Index Fund; iShares Nasdaq Biotechnology Index Fund; iShares Dow Jones U.S. Real Estate Index Fund; Nasdaq-100 Index Tracking Stock; Standard & Poor's Depository Receipts; Standard & Poor's MidCap 400 Depository Receipts; Select Sector SPDR Fund; Semiconductor HOLDRS; Retail HOLDRS; and Oil Service HOLDRS

Dear Ms. Jackson:

The International Securities Exchange, LLC hereby files Amended Forms 19b-4(e), with respect to above listed products. These securities are listed for trading pursuant to ISE Rules 2123 and 2124.

Sincerely,

A handwritten signature in black ink, appearing to read "MJS", is written over a faint, larger version of the same signature.

Michael J. Simon
General Counsel and Secretary

Attachment

END